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Aldosterone is released from adrenal zona glomerulosa (ZG) cells and plays an important
role in Na and K homoeostasis. Mutations in the human inwardly rectifying K channel CNJ
type (KCNJ) 5 (KCNJ5) gene encoding the G-coupled inwardly rectifying K channel 4 (GIRK4)
cause abnormal aldosterone secretion and hypertension. To better understand the role of
wild-type (WT) GIRK4 in regulating aldosterone release, we have looked at aldosterone se-
cretion in a Kcnj5 knockout (KO) mouse. We found that female but not male KO mice have
reduced aldosterone levels compared with WT female controls, but higher levels of aldos-
terone after angiotensin II (Ang-II) stimulation. These differences could not be explained by
sex differences in aldosterone synthase (Cyp11B2) gene expression in the mouse adrenal.
Using RNAseq analysis to compare WT and KO adrenals, we showed that females also have
a much larger set of differentially expressed adrenal genes than males (395 compared with
7). Ingenuity Pathway Analysis (IPA) of this gene set suggested that peroxisome proliferator
activated receptor (PPAR) nuclear receptors regulated aldosterone production and altered
signalling in the female KO mouse, which could explain the reduced aldosterone secretion.
We tested this hypothesis in H295R adrenal cells and showed that the selective PPARα ag-
onist fenofibrate can stimulate aldosterone production and induce Cyp11b2. Dosing mice
in vivo produced similar results. Together our data show that Kcnj5 is important for baseline
aldosterone secretion, but its importance is sex-limited at least in the mouse. It also high-
lights a novel regulatory pathway for aldosterone secretion through PPARα that may have
translational potential in human hyperaldosteronism.
Introduction
Aldosterone plays a central role in blood pressure regulation, and its dysregulation is seen as increas-
ingly important in hypertension. Up to 10% of hypertension is now attributed to primary aldosteronism
(PA), characterized by autonomous aldosterone production, independent of the renin–angiotensin path-
way [1]. Recent guidance suggests that a third of PA patients have unilateral aldosterone producing ade-
nomas (APAs) in an adrenal gland [1]. Exome sequencing has also shown that over a half of these APAs
harbour somatic mutations in the potassium channel encoding gene, inwardly rectifying K channel CNJ
type (KCNJ) (KCNJ5) [2-4]. The importance of theseKCNJ5mutations in PA has been reviewed in detail
[5,6].
The prevalence of KCNJ5mutations in APAs varies between cohorts, with up to 70% of APAs in some
south Asian cohorts harbouring KCNJ5 mutations [7]. KCNJ5 encodes a G-protein regulated inwardly
rectifying potassium channel (GIRK4), with the majority of mutations identified in APAs affecting the
cation selectivity of this channel, and resulting in increased Na+ permeability [2,8,9]. The current consen-
sus posits that this increased Na+ permeability of the mutant GIRK4 allows Na+ influx into the normally
hyperpolarized aldosterone-producing cells of the zona glomerulosa (ZG) causing them to depolarize
[4]. This depolarization opens voltage-gated calcium channels that activate Ca2+/calmodulin-dependent
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protein kinases, increasing transcription of aldosterone synthase (CYP11B2) and eventually increasing aldosterone
production.
Despite extensive characterization of the KCNJ5 mutations identified in APAs, little is known about the role or
importance of the wild-type (WT) GIRK4 channel in aldosterone regulation. Yet,KCJN5 is expressed at higher levels
in the adrenal than the atria (http://www.gtexportal.org/home/gene/KCNJ5) where its role in themuscarinic currents
in the heart is well understood. This differential expression of transcript in the adrenal is also seen for other potas-
sium channels such as the two-pore K channel (K2P) TASK1 (KCNK3) channel (http://www.gtexportal.org/home/
gene/KCNK3). The ZG cells have been shown to have a resting membrane potential of approximately −80 mV, close
to the Ek of potassium (−90 mV) in these cells, and TASK channels are thought to be important contributors to the
high resting K permeability of rodent ZG cells [10,11]. WT GIRK4 channels, probably as heterotetrameric channels
with KCNJ3, could contribute to the basal hyperpolarization of the ZG cell. Equally they may have a role in ZG repo-
larization after they are depolarized in response to ATII, since the Gβγ subunits liberated activate GIRK4 channels
[12,13]. This would suggest an inhibitory role for the channel, resulting in the ZG cell requiring a larger depolarizing
stimulus for aldosterone production.
By utilizing the previously established KCNJ5 (GIRK4) (−/−) knockout (KO) mouse line [14,15], we have investi-
gated the role of WT GIRK4 in the mouse adrenal and its impact on aldosterone secretion.
Methods
Animals and tissue collection
Kcnj5 (−/−) KO mice
They were a generous gift from Dr Kevin Wickman (Department of Pharmacology, University of Minnesota, Min-
neapolis, MN, U.S.A.) and Dr Matteo Mangoni (Centre National de Recherche Scientifique (CNRS UMR 5203), De-
partment of Physiology, Montpelier, France) and were maintained in Cambridge by outcrossing with WT C57/BLJ6
mice that were also used as the littermate controls, animals were used for experiments aged 13–16 weeks [14,15]. The
KCNJ5 genotype of each mouse used was confirmed by PCR: neomycin primers 5′ ATGGATTGCACGCAGGTT 3′,
5′ GATACCGTAAAGCACGAGGAAG 3′; coding exon 1 (exon 3 modern mRNA), 5′ TAGAACCACAGGACACC-
TAGTGAG 3′, 5′ CATTGCCTACGGACGGG 3′. The animal research was regulated under U.K. law, specifically the
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University
of Cambridge Animal Welfare and Ethical Review Body.
Immunohistochemical staining
Formaldehyde fixed paraffin embedded (FFPE) samples were cut using a microtone to 5-μM sections. Sections
were deparaffinized in histoclear II (National Diagnostics, Atlanta, GA) and dehydrated in graded ethanol ending
in ddH2O. Antigen retrieval was performed using standard procedure in the 2100-Retriever (http://www.aptum-bio.
com) using commercial universal antigen retrieval solution (http://www.aptum-bio.com).
Mounted tissue sections were stained using the Envision DAB enhancer kit from Dako following manufacturer’s
protocol with anti-DAB2 (disabled 2) (http://www.bdbiosciences.com). The following commercial antibodies were
used:
Target Manufacturer Catalogue number Dilution
KCNJ5 Alomone APC-027 WB 1/200
IHC 1/20
KCNJ5 Sigma HPA017353 WB 1/250
IHC 1/100
KCNJ5 Santa Cruz Biotechnology A-14 WB 1/200
KCNJ5 Santa Cruz Biotechnology H-60 WB 1/200
KCNJ5 Abcam ab125099 WB 1/200
DAB2 BD Biosciences 610464 IHC 1/1000
LCM 1/500
Laser capture microdissection
Anoptimized immunohistochemicalprotocolusing theEnvisionPlus IHC kit fromDAKOwas used to stainDAB2. In
brief, FFPE 5 μM sections mounted on to slides were rapidly rehydrated through Histoclear II and reducing ethanol
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solutions, each for 20 s. Antigen retrieval was performed at 60◦C overnight with universal antigen retrieval solu-
tion (AptumBiologicals, https://www.proteogenix-products.com), peroxidases blocked for 10min, and both primary
(anti-DAB2) and secondary antibodies incubated for 10 min each. Between each step, slides were washed twice for 1
min in PBS. Following staining, slides were rapidly dehydrated in ascending ethanol solutions for 20 s each, ending
with 100% ethanol, allowed to dry and used immediately for laser capture. Laser capture was performed on a Leica
LMD6, with samples falling directly into lysis buffer before immediate extraction using the Qiagen RNeasy FFPE kit
(https://www.qiagen.com) according to manufacturer’s instructions.
Plasma collection and electrolyte measurement
Animals were anaesthetized under 3% isoflourane in O2 and a terminal blood sample collected by cardiac puncture;
blood was immediately transferred to lithium heparin coated tubes for plasma collection. This fresh blood was also
analysed on the iSTAT using EC8+ cartridges (www.pointofcare.abbott). Plasmawas removed, snap frozen and stored
at −80◦C.
Aldosterone assay
Aldosterone was measured from 10 μl frozen plasma using the Cisbio aldosterone assay kit according to manufac-
turer’s instructions (www.cisbio.com), in which charcoal-stripped serumwas used for dilution of the assay standards.
RNAseq sample preparation and sequencing
TotalRNA, includingmiRNAwas extractedusingQiagenmiRNeasy kit from 16wholemouse adrenals taken froman-
imals between 13 and 16weeks of age, four from each group;maleWT (+/+),maleKCNJ5 (−/−), femaleWT and female
KCNJ5 (−/−). Quality of extracted RNA was analysed using an Agilent TapeStation (www.genomics.agilent.com),
all RNA samples reached RIN numbers >9. The RNAseq analysis was performed by Cambridge Genome Ser-
vices (www.genomicservices.path.cam.ac.uk) using Ilumina Mouse WG6 beadchips (approximately 45000 mark-
ers mapped to NCBI RefSeq build 36.2, release 22) and analysed using the EdgeR Bioconductor package (https:
//bioconductor.org/packages/release/bioc/html/edgeR.html). Pathway analysis of the differentially expressed genes
was performed with the Ingenuity Package Analysis (IPA R©) software package (https://www.qiagenbioinformatics.
com/products/ingenuity-pathway-analysis/). The RNAseq data used in this manuscript have been publically de-
posited on GEO.
H295R culture and treatments
H295R cells weremaintained as described previously [16].Cells were treatedwith thedescribed drugs orDMSO as ve-
hicle control for 24 h after plating in 96-well plates. The following drugs were used: rosiglitazone (www.sigmaaldrich.
com R2408), fenofibrate (www.sigmaaldrich.com F6020) or GW 6471 (www.sigmaaldrich.com G5045). For the last
24 h of treatment, cells were also treated with 10 nM angiotensin II (Ang-II) (www.sigmaaldrich.com, A9525) +− 10
nM losartan (www.sigmaaldrich.com 61188). At the final time point, medium was removed for aldosterone quantifi-
cation and cell viability measured by MTT assay as described previously [16]. Aldosterone production was normal-
ized by viability within each well. For gene expression experiments, medium was discarded and cells lysed for RNA
extraction using Purelink RNA extraction kit (www.thermofisher.com).
Gene expression
Reverse transcription was carried out using Superscript IV (www.thermofisher.com) as per manufacturer’s protocol.
Gene expression analysis was carried out using the TaqMan R© Fast Advanced Master Mix and validated TaqMan R©
Gene Expression Assays according to manufacturer’s protocol (www.thermofisher.com) on an ABI 7500 platform.
Probes used: mouse CYP11B2, FAM-MGB, Mm01204955 g1, mouse KCNJ5, FAM-MGB, Mm01175829 m1 and eu-
karyotic 18S, VIC-MGB, 4319413E. Relative gene expression was calculated by the CT method against 18S as the
housekeeper and expressed as a multiple of the control value (set to 1) [17].
Statistics
Normally distributed data were analysed by ANOVA with post-hoc testing or Student’s t tests as appropriate using
Prism 6 software (www.graphpad.com). Significance was taken as P<0.05.
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Figure 1. Representative sections of male and female WT (+/+) and KO (−/−) mouse adrenals stained for DAB2
Results
Adrenal morphology of Kcnj5 (−/−) KO mice is unchanged
There were no obvious macroscopic differences between the adrenal glands recovered from KCNJ5 KO (−/−) com-
pared with WT (+/+) mice. Sections of the glands also showed that zonation between the cortex and medulla (M) was
maintained. Using the specific disabled 2 (DAB2) marker [18], the ZG also had a similar depth in both KO (−/−) and
WT (+/+) glands (Figure 1 below).
Kcnj5 is speciﬁcally expressed in the mouse ZG
We next determined the expression and localization of Kcnj5 in the adrenal gland of WT (+/+) C57BL/6 mice. Due
to the lack of a commercially suitable antibody with specificity for the channel in the mouse (Supporting Data), we
carried out Kcnj5 gene expression analysis by qPCR of WT (+/+) mouse adrenal tissue. The specificity of the KCNJ5
gene expression assay was confirmed by gene expression analysis in WT (+/+) and KCNJ5 KO (−/−) brain and adrenal
cDNA (Supporting Data).
To confirm that Kcnj5 was specifically expressed in the outer ZG, as in the human adrenal cortex, laser capture
microdissection was used to recover tissue from the ZG, zona fasciculata (ZF) and M. We confirmed successful mi-
crodissection by examining Cyp11B2 gene expression as a specific marker for the ZG (Figure 2 below). This showed
that only cDNA extracted from the ZG expressed both Cyp11B2 and Kcnj5 genes, confirming that in the mouse
Kcnj5 is expressed specifically by the aldosterone-producing cells of the ZG.
Female Kcnj5 (−/−) KO mice display lowered plasma aldosterone levels
We measured plasma aldosterone levels in male and female adult KCNJ5 KO (−/−), heterozygous (+/−) and WTmice
(+/+), both at baseline and 30 min after an Ang-II challenge (200 mg/kg IP). Female WT mice displayed significantly
higher plasma aldosterone levels than age-matched WT males (Figure 3). Basal plasma aldosterone levels were also
unchanged across genotypes in male mice (Figure 3A below). In contrast, female Kcnj5 KO animals had significantly
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Figure 2. YP11B2 and KCNJ5 gene expression in laser captured adrenal zones
(A) DAB2-stained adrenal section before (A) and after (B) laser capture of specific adrenal zones. Relative gene expression of
Cyp11B2 (C) and KCNJ5 (D). Bars are means of two experiments in laser captured tissue. (E) (Inset) shows gel separation of qPCR
products for (D). Abbreviations: ND, not detected by 45 cycles; ntc, no template control.
Figure 3. Differences in basal and Ang-II stimulated aldosterone levels and adrenal CYP11B2 gene expression in mice by
genotype and sex.
(A) Basal plasma aldosterone levels in male and female KO (KCNJ5−/−), heterozygous (KCNJ5+/−) and WT (KCNJ5+/+) mice (n=7).
*P<0.05 compared with male WT, **P<0.05 compared with female WT. (B) Levels of Cyp11B2 expression in WT compared with KO
male and female mice (n=4). (C) Levels of plasma aldosterone before and 30 mins after Ang-II in male and female KO (KCNJ5−/−)
mice (n=4–7). *P<0.05 compared with basal, #P<0.05 male compared with female KO. Bars are mean +− S.E.M.
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. iSTAT blood and haematocrit measurements and body weight for WT (+/+), heterozygous (+/−), and KO (−/−) mice
by sex
The horizontal lines are mean +− S.E.M. for n=4–7 mice. *P<0.001 male compared with female.
lower basal plasma aldosterone levels than femaleWT littermates. The levels in heterozygous females were intermedi-
ate. These differences were not explained by differences in Cyp11B2 gene expression (Figure 3B below). Aldosterone
levels after Ang-II challenge were significantly higher in female compared with male KO mice, despite having similar
basal levels of aldosterone (Figure 3C below).
Electrolytes
Blood electrolytes in male and female Kcnj5-deficient mice were measured in fresh whole blood using an iSTAT
device. The blood levels of K showed a downward trend from WT to homozygous KO and were consistently lower
in females compared with males. However, neither of these trends were statistically significant. No differences were
observed between sexes or genotypes in blood levels of sodium, chloride, glucose, urea, HCO3 or percentage haema-
tocrit. There was also no significant difference in body weight between genotypes, although males were significantly
heavier than females throughout (Figure 4).
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Figure 5. Venn diagram representation of the differentially expressed genes (female compared with male) in adrenals from
WT and KO (KCNJ5−/−) mice
The top seven genes in both gene lists are identical.
RNAseq reveals major sex differences in the mouse adrenals
To explore themolecular basis for the sex differences in aldosterone secretion, we carried out RNAseq analysis of WT
and Kcnj5 (−/−) KO adrenals from both male and female mice. The RNAseq results showed that many more genes
were differentially expressed in females compared with males (Table 1 below).
The five differentially expressed genes in the male did not include any genes plausibly linked to aldosterone pro-
duction (Supplementary Data online). Of note, Kcnj5 was itself overexpressed in both male and female KO adrenals
(Supplementary Data online). However, the Sashimi plot (Supporting Data) of the RNAseq data showed that exon 3
of Kcnj5 was not expressed in keeping with its deletion and replacement with a neomycin resistance gene (Neor) in
the deletion cassette. This explains our failure to detect a full-length Kcnj5 cDNA on qPCR of the Kcnj5 KO (−/−)
adrenals.
We then compared the genes differentially expressed in male compared with female WTmice and those expressed
inmale comparedwith female KCNJ5 (−/−) KO adrenals. This identified 184 genes that were shared betweenWT and
Kcnj5 (−/−) KO adrenals (Figure 5, below). In both analyses, sex-specific genes encoded on theX and Y chromosomes
(Uty, Eif2s3y, Kdm5d and Xist) were ranked among the top ten differentially regulated genes (Supplementary Data).
Two aldo-keto reductases Akr1c18 and Akr1d1 were down-regulated in females of both genotypes compared with
their male counterparts, and the potassium channel encoding gene Kcnk1 had a consistently lower gene expression
in males compared with females of the same genotype. There were also a number of differentially expressed genes
unique to each genotype, including the Y chromosome gene Ddx3y, that was only differentially expressed in WT
adrenals.
Pathway analysis of differentially expressed genes suggests that PPAR
pathways regulate aldosterone secretion
To look for functional connections between the differentially expressed genes in the female adrenals, we undertook
pathway analysis using the Ingenuity R© software package (Ingenuity Pathway Analysis (IPA)) using the genes differ-
entially expressed (log2FC >+−1.5) between female WT and Kcnj5 KO (−/−) adrenals. This identified five canonical
pathways and upstream regulators that highlighted a major role for the RXR nuclear receptor in controlling adrenal
function (Table 2 below). RXR is in turn regulated by forming heterodimers with peroxisome proliferator activated
receptor (PPAR) α and PPARγ. This analysis also predicted that the pathways through these nuclear receptors were
uniformly down-regulated in the KO female adrenals.
Activation of PPARα but not PPARγ leads to Ang-II-independent
aldosterone production in H295R cells
IPA of the adrenal RNAseq data suggested that PPARα- and PPARγ-mediated pathways were involved in regulating
adrenal aldosterone production. To test this in vitro, we exposed adrenal H295R cells to PPAR pathway agonists. The
PPARγ agonist, rosiglitazone (10 μM), produced no significant change in aldosterone production from H295R cells
treated for 48 h with the drug (Figure 6, below). However, rosiglitazone effectively blocked aldosterone production
stimulated by 10 nM Ang-II for 24 h, suggesting that PPARγ activation may inhibit Ang-II-mediated aldosterone
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Aldosterone production by cultured H295R adrenal cells exposed to PPAR agonists
(A) Aldosterone production from H295R cells treated with either control (0.1% DMSO) or 10 μ PPAR agonists: rosiglitazone (Rosi,
PPARγ) or fenofibrate (Feno, PPARα) for 48 h. Cells were also treated for the final 24 h with 10 nM Ang-II or Ang-II with 10 nM
losartan (Ang-II + L). Error bars represent S.E.M. of n=4. *P<0.05 compared with basal control, **P<0.05 compared with basal of
same treatment, #P<0.05 compared with Ang-II of same treatment. (B) CYP11B2 gene expression in H295R cells treated for 24
h with either control (DMSO), 10 μM fenofibrate, 10 μM fenofibrate with GW6471 or 10 μM GW6471 alone. Error bars represent
S.E.M. of n=4. *P<0.05 compared with control, #P<0.05 compared with Feno.
Figure 7. Effect of in vivo administration of fenoﬁbrate on plasma aldosterone levels and adrenal CYP11B2 gene expression
(A) Effect of 7 or 14 days administration of fenofibrate (100 mg/kg PO) or vehicle (olive oil) on plasma aldosterone levels in female
WT mice. *There is a significant treatment effect on two-way ANOVA (P=0.003). (B) Expression of CYP11B2 in the adrenals after
14 days of dosing with fenofibrate (Feno) or vehicle, *P<0.05 compared with control. Bars are mean +− S.E.M. for n=4.
production. In contrast, cells treated with the PPARα agonist, fenofibrate (10 μM), showed a significant Ang-II inde-
pendent increase in aldosterone production. This increase in aldosterone production was accompanied by a signifi-
cant elevation in Cyp11b2 gene expression after 24 h fenofibrate treatment, which could be reversed by addition of
the specific PPARα antagonist GW6471.
PPARα activation causes aldosterone production in female mice
To see if the in vitro effect of PPARα activation on aldosterone production could occur in vivo,WT femalemice were
treated with fenofibrate (100 mg/kg PO) or vehicle (olive oil) daily for 2 weeks. Mice that received fenofibrate showed
a significant increase in plasma aldosterone levels compared with control treated mice, but the effect was masked by
the effect of the olive oil vehicle on aldosterone production (Figure 7, below). There was also a modest increase in
Cyp11B2 gene expression in adrenals from fenofibrate treated mice compared with control (Figure 7). Together this
supported the in vitro finding in H295R cells, showing that activation of PPARα by fenofibrate leads to increase in
aldosterone production.
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Discussion
Interest in the role of theGIRK4 K channel in controlling adrenal aldosterone production has emerged only in the last
few years with the discovery that both germline and somatic mutants in the KCNJ5 gene cause hyperaldosteronism
[2,5]. However, there are no data on the role played by the WT GIRK4 channel in the normal adrenal. Our studies
reported here show that female but not male Kcnj5-deficient mice have lowered plasma aldosterone levels compared
with WT counterparts. This finding is mirrored by the observation of transcriptional changes in the female Kcnj5
(−/−) KO adrenal, which are not present in male Kcnj5 (−/−) KO adrenals. IPA analysis indicated that the pattern of
differentially expressed genes in the female KCNJ5 KO compared with WT adrenals implicated PPARα and PPARγ
pathways in the regulation of aldosterone secretion. We have confirmed the role of PPARα by demonstrating that
activation of PPARα with fenofibrate, a specific agonist for this nuclear receptor, increases aldosterone production
both in adrenal H295R cells and mice.
In the present study, therewere genderdifferences in plasma aldosteronewith the female having significantly higher
levels than age-matched males. Even larger female over males differences in plasma aldosterone were reported in the
C57/BL6J strain by Heitzmann et al. [19]. In parallel with these differences in aldosterone levels, we have identified
major differences in the adrenal transcriptome of the female compared with male mice. Sexual dimorphism within
the renin–angiotensin system is well documented and gender differences in WT adrenal gene expression was first
reported by El Wakil et al. [20]. They found some 269 genes that were differentially expressed in male compared with
female WT mouse adrenals. Other studies have also reported sex differences in adrenal phenotype, morphology and
gene expression in both inbred strains and genetically modified mice [21-23]. For example, a microarray analysis of
KCNK3 (TASK1) KO (−/−) mice showed differences in gene expression and phenotype between female and male
mice, with castrated male mice having a similar gene expression profile to sham-operated female mice [24].
We found that like human ZG mRNA forKCNJ5 was readily detected in the ZG of the mouse, although it has been
reported that KCNJ5 mRNA was undetectable in the rat adrenal cortex (ZG or ZF) [25]. Chen et al. [25] also failed
to show staining for KCNJ5 protein. However, in our hands, the antibody they used did not give specific staining for
KCNJ5 protein in either IHC sections or Western blots from the mouse adrenal cortex (Supplementary Figure S1).
Hence, although we could detect KCNJ5 message, the lack of a specific antibody for mouse KCNJ5 meant we could
not confirm that protein was also present in the mouse ZG.
A striking feature of the RNAseq experiments was the finding that KCNJ5 gene products were up-regulated in the
KO mice of both sexes. However, the mouse KCNJ5 mRNA is composed of four exons, but only two code for the
mature 419aa protein and the majority of this coding region lies in exon 3. In the KO mice, exon 3 has been swapped
for a Neor coding region, so although the qPCR analysis used a commercial Taqman primer-probe set that maps to
the exon 3–4 boundary (Mm01175829 m1, Thermo Fisher), it will only amplify mature mRNA with both coding
exons present. This explains our failure to detect a qPCR signal from the KO mice. This was an important negative
control, since none of the commercially available antibodies could identify an appropriately sized band for mature
GIRK4 protein that was absent from the KO adrenal. It is also notable that other inwardly rectifying K channels were
not present among the genes differentially expressed in male or female KO adrenals. It might be expected that loss of
GIRK4 activity could be compensated by altered expression of other inward-rectifying K channels. However, we saw
no evidence of this in the RNAseq data.
We have identified 170 differentially expressed genes between sexes of our WT adrenals (using a threshold of a
four-fold change), and 273 in adrenals fromKcnj5 (−/−) KO mice. Indeed, the top seven genes from both lists actually
overlapped between genotypes (Figure 5). Interestingly, of these seven genes, all three genes that were up-regulated in
females (Xist, Akr1c18 andAkr1d1) were also up-regulated in the study by El Wakil et al. [20]. This finding confirms
the robustness of RNAseq in correctly identifying differentially expressed genes, as we and El Wakil et al. [20] used
different platforms yet identified very similar gene lists. Of the down-regulated genes however, only one gene, Uty,
was consistent between ours and the El Wakil et al. [20] study. However, a large number of other down-regulated
genes were consistent between our WT or Kcnj5 (−/−) KO sex comparisons: including Srd5a2, Hmox1, Acan and
Susd3, all of which featured in the top 20 differentially expressed genes in both comparisons (see Supplementary
Data). Srd5a2 encodes type 2 5α-reductase (3-oxo-5-α-steroid 4-dehydrogenase 2), an enzyme responsible for the
reduction in keto-steroids, including corticosterone, testosterone and aldosterone to their reduced metabolites. In
female adrenals, the aldo-keto reductases, Akr1c18, and Akr1d1 are highly expressed, and Akr1d1 encodes steroid
5β-reductase which like 5α-reductase converts keto-steroids into their reduced metabolites. Similarly, the Akr1c
family of aldo-keto reductases are implicated in progesterone metabolism [26]. The sexual dimorphism in mouse
adrenal gene expression is intriguing considering the female predominance in human of APAs expressing KCNJ5
somatic mutations. A meta-analysis of published data on KCNJ5 somatic mutations showed 67% of them occurred
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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in females [27-29]. Conceivably, KCNJ5mutations could have a greater phenotypic impact on female compared with
male adrenal cells because of a greater physiological importance of GIRK4 in the female adrenal. Based on the data
presented here, this seems to be the case at least for the mouse. A sex difference in the aldosterone phenotype was
also reported in the ITask1 KO mouse with only female adults displaying hyperaldosteronism [24]. The males were
unaffected and appeared to be protected by androgen-regulated up-regulated expression of Task3 channels.However,
it is important to note that H295R cells that are routinely used as an in vitro model of human adrenocortical cells and
were used in our work are karyotypically female (https://www.lgcstandards-atcc.org/products/all/CRL-2128.aspx).
Therefore, sublines derived from H295R such as HAC15 are also female. Hence, there is not an easy cell-based ap-
proach to explore the hypothesis that somatic KCNJ5 mutations have a larger effect on aldosterone production if
expressed in female compared with male adrenal cells.
Previous work with H295R or HAC15 cells reported that incubation with PPARγ agonists reduced aldosterone
production, although reported effects on CYP11B2 mRNA expression are inconsistent [30,31]. However, we could
not reproduce these findings using rosiglitazone (Figure 6). At the PPARγ agonist concentrations previously used (10
μM), we found that cell viability was markedly impaired after 72 h of culture (results not shown), which may explain
some of the apparent reduction in aldosterone levels reported beyond 48-h incubation. Our findings with the PPARα
agonist fenofibrate are clearer with substantial increases in both aldosterone secretion and Cyp11B2 mRNA levels.
Since the effect is blocked by the selective antagonist GW6471, fenofibrate is selectively acting through PPARα. It has
been suggested previously that renin may be under PPARα regulation [32], but stimulation of aldosterone secretion
by fenofibrate has not been reported before and was only revealed here from our IPA analysis. The IPA analysis also
suggests that the PPARα pathway is deactivated in the KO mouse adrenal, which may explain at least in part why
female mice have lower aldosterone levels. Further work is needed to explore the precise mechanism connecting
PPARα signalling and aldosterone secretion, but it is clear that this effect is not simply explained by altered RXR or
Pparα expression. A more detailed steroid profiling of the female KO mouse or a metabolomics approach may give
important clues to the molecular pathways involved.
In summary, we have shown that Kcnj5 is functionally important for aldosterone secretion in the mouse but it is
gender specific. The reduced aldosterone secretion in the female KO mouse may be explained by reduced PPARα
signalling, which represents a novel control pathway for aldosterone. Hence, blockade of PPARα signalling may have
translational potential in regulating human hyperaldosteronism, although this strategy may be sex limited.
Clinical perspectives
• Mutations in the the potassium channel, KCNJ5, have been recently identified as a cause of hyper-
aldosteronism in human hypertension. To further explore the role of KCNJ5 in the adrenal gland, we
looked at the phenotypic impact in the KO mouse.
• Female but not male mice with homozygous knock of KCNJ5 have reduced circulating levels of
aldosterone. We used RNAseq to probe the molecular basis for this difference comparing WT and
KO adrenals. The female adrenal has a much larger set of differentially expressed genes compared
with the male (396 compared with 7) and pathway analysis of these genes suggested that PPARα
was an important regulator of aldosterone synthesis.
• Our work suggests that KCNJ5 has a role in basal as well as pathological aldosterone secretion,
although in the mouse, this basal effect may be sex limited. We have also identified a novel regulator
of aldosterone secretion that has translational potential to the human adrenal.
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